How does Duavee work for perimenopause?

Duavee is the brand name for a fixed-dose combination of conjugated estrogens (CE) and bazedoxifene (BZA), a selective estrogen receptor modulator (SERM). Together they form what researchers call a tissue-selective estrogen complex, or TSEC. This pharmacological pairing was designed to allow women with a uterus to receive systemic estrogen for symptom relief without needing to take a separate progestogen component to protect the uterine lining, thus avoiding the side effects that progestogens cause for some women.

To understand how Duavee works, it helps to first understand the problem it was engineered to solve. In standard combined hormone therapy, estrogen is paired with a progestogen to prevent unopposed estrogen from stimulating the endometrial lining, which would otherwise lead to endometrial hyperplasia and elevated cancer risk. Progestogens are effective for this purpose but can produce side effects including mood changes, bloating, breast tenderness, and spotting in some women. Bazedoxifene, the SERM component of Duavee, serves as the uterine protectant in place of a progestogen. SERMs work by binding to estrogen receptors but producing different effects in different tissues, some agonistic (estrogen-like) and some antagonistic (blocking estrogen), depending on the tissue type.

In the uterus, bazedoxifene acts as an estrogen antagonist: it blocks estrogen receptors in the endometrial lining, preventing the conjugated estrogens in Duavee from stimulating endometrial growth. This provides endometrial protection without the need for progesterone or a synthetic progestin. In bone tissue, bazedoxifene acts as an estrogen agonist, supporting bone mineral density. In breast tissue, bazedoxifene is neutral to antagonistic, which is one of the reasons it was considered as a pairing with estrogen rather than progestin.

The estrogen component, conjugated estrogens, provides the familiar symptom-relief functions of estrogen therapy: stabilizing the hypothalamic thermostat to reduce hot flashes and night sweats, supporting neurotransmitter balance for mood and sleep, and addressing the systemic effects of estrogen deficiency. Clinical trials in the SMART (Selective estrogens, Menopause And Response to Therapy) program demonstrated that Duavee significantly reduced hot flash frequency and severity compared to placebo, with endometrial safety maintained without requiring a progestogen.

FDA approval for Duavee covers two indications: treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) in postmenopausal women with a uterus, and prevention of postmenopausal osteoporosis in the same population. It is approved for postmenopausal women, not women who are still menstruating.

Several important limitations of Duavee are worth understanding. Because bazedoxifene is an estrogen antagonist not just in the uterus but also in vaginal tissue, Duavee does not improve vaginal dryness the way that pure estrogen therapy does. Women who have significant genitourinary symptoms alongside hot flashes may therefore need additional local vaginal estrogen treatment even while using Duavee. This is a practical limitation compared to estrogen-progestogen combinations, which do not have this constraint.

Duavee is available as an oral tablet only, meaning the convenience of transdermal estrogen delivery (with its associated lower clot risk) is not available in this formulation. Like all estrogen-containing therapies, it carries risk of venous thromboembolism and is contraindicated in women with a history of blood clots or stroke. Common side effects reported in trials include muscle spasms, nausea, diarrhea, dyspepsia, and abdominal pain. As a SERM, bazedoxifene shares the class effect of increased hot flash frequency seen with some SERMs, though this effect has been modest in Duavee trials compared to bazedoxifene alone.

The comparison between Duavee and standard estrogen-progestogen therapy is worth considering practically. Women who have previously had difficult experiences with progestogen components, whether from synthetic progestins causing mood changes or from micronized progesterone causing sedation, may find the progestogen-free approach of Duavee meaningfully improves their quality of life on treatment. Conversely, women who need treatment for both hot flashes and vaginal symptoms may require the addition of a separate vaginal estrogen product alongside Duavee, which adds complexity and cost. Discussing these practical trade-offs with a provider who is familiar with the full range of perimenopausal treatment options is important before making a choice.

Tracking your symptoms over time, using a tool like PeriPlan, can help you assess whether Duavee is adequately controlling your hot flashes and note any side effects or residual genitourinary symptoms that might need additional treatment.

When to talk to your doctor: Duavee requires a prescription and a full assessment of your cardiovascular, cancer, and bone health history. It is a particularly relevant option if you have found progestogen side effects difficult to tolerate in previous hormone therapy attempts. Discuss with your provider whether vaginal estrogen should be used alongside it if dryness is also a concern, since Duavee does not address genitourinary symptoms.

This content is for informational purposes only and does not replace medical advice. Always consult your healthcare provider about your specific situation.